124436-59-5 | Pirodavir

Packsize	Purity	Availability	Price	Discounted Price
1mg	≥98%	in stock	$42.00	$29.00
5mg	95%	in stock	$122.00	$85.00
10mg	95%	in stock	$177.00	$124.00
25mg	95%	in stock	$237.00	$166.00
50mg	95%	in stock	$403.00	$282.00
100mg	95%	in stock	$683.00	$478.00
250mg	95%	in stock	$1,160.00	$812.00

Description

• Catalog Number: AA28334
• Chemical Name: Pirodavir
• CAS Number: 124436-59-5
• Molecular Formula: C21H27N3O3
• Molecular Weight: 369.4574
• MDL Number: MFCD00866965
• SMILES: CCOC(=O)c1ccc(cc1)OCCC1CCN(CC1)c1ccc(nn1)C

Computed Properties

• Complexity: 446
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 27
• Hydrogen Bond Acceptor Count: 6
• Rotatable Bond Count: 8
• XLogP3: 3.7

Literature

• Study of the biological activity of novel synthetic compounds with antiviral properties against human rhinoviruses.

  Molecules (Basel, Switzerland) 20110426

• Pharmacophore-based design, synthesis, and biological evaluation of novel chloro-pyridazine piperazines as human rhinovirus (HRV-3) inhibitors.

  Bioorganic & medicinal chemistry letters 20110201

• [Establishment of isolated rabbit airway smooth muscles responsiveness model for the pharmacodynamic study of anti-rhinoviruses drugs].

  Yao xue xue bao = Acta pharmaceutica Sinica 20100401

• Synthesis and evaluation of novel chloropyridazine derivatives as potent human rhinovirus (HRV) capsid-binding inhibitors.

  Bioorganic & medicinal chemistry 20090115

• Isothiazole derivatives as antiviral agents.

  Antiviral chemistry & chemotherapy 20070101

• 2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binder.

  Bioorganic & medicinal chemistry letters 20050415

• In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity.

  Antimicrobial agents and chemotherapy 20040501

• Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics.

  Journal of medicinal chemistry 20031009

• An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus.

  Journal of medicinal chemistry 20030717

• Synthesis of new 3-methylthio-5-aryl-4-isothiazolecarbonitriles with broad antiviral spectrum.

  Antiviral research 20020801

• Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics.

  Journal of medicinal chemistry 20020411

• The viral protein 3CD induces an equilibrium between the viral protein and RNA synthesis in a cell-free system for poliovirus replication.

  Archives of virology 20020401

• In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease.

  Antimicrobial agents and chemotherapy 19991001

• Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.

  Journal of medicinal chemistry 19990408

• In vitro studies of the antirhinovirus activity of soluble intercellular adhesion molecule-1.

  Antimicrobial agents and chemotherapy 19920601

• In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity.

  Antimicrobial agents and chemotherapy 19920101